Novartis’ CAR-T therapy gets second FDA approval – PharmaTimes
PharmaTimes |
Novartis’ CAR–T therapy gets second FDA approval
PharmaTimes The FDA has approved Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for intravenous infusion for its second indication – the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic … Two major advances for CAR T-cell cancer treatment6abc.com FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell …Curetoday.com Novartis and Gilead’s CAR–T Therapies Now Compete for the Same Cancer PatientsLabiotech.eu (blog) Benzinga –MarketWatch –PR Newswire (press release) all 26 news articles » |
Technology Networks |
T Cell Biomarker Predicts Response to CAR T Cell Therapy
Technology Networks Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are … |
Technology Networks |
T Cell Biomarker Predicts Response to CAR T Cell Therapy
Technology Networks Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are … |
Business Wire (press release) |
Evotec Expands CRISPR-Based Technology Offering with Licence from ERS Genomics
Business Wire (press release) The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others. Dr Mario Polywka, Chief Operating Officer of Evotec … Evotec Adds Licence From ERS Genomics To CRISPR Service Offering – Quick FactsNasdaq DGAP-News: EVOTEC EXPANDS CRISPR-BASED TECHNOLOGY OFFERING WITH LICENCE FROM ERS GENOMICSMarkets Insider ERS Genomics Licenses CRISPR/Cas9 Genome Editing Patents to EvotecWV News |
|
BioLamina Launches a Cell Therapy Grade Stem Cell Culture Matrix, Biolaminin 521 CTG, Bridging Discovery and …
PR Newswire (press release) Since 2009, BioLamina has been providing the stem cell research community with high quality research reagents that are often crucial for the potential cell therapy manufacturing process. BioLamina’s best-selling product is human recombinant laminin 521 … |